Aducanumab

Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ) . Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research[1].

Product Specifications

CAS Number

[1384260-65-4]

Product Name Alternative

BIIB037

UNSPSC

12352203

Target

Amyloid-β

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/aducanumab.html

Purity

99.25

Solubility

H2O

Smiles

[Aducanumab]

Molecular Weight

(146.2 kDa)

References & Citations

[1]Sevigny J, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016 Sep 1;537 (7618) :50-6. |[2]Kastanenka KV, et al. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. J Neurosci. 2016 Dec 14;36 (50) :12549-12558.